argenx SE - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ARGX Nasdaq 2830 argenx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for argenx SE

High Growth Tech Stocks in Europe with Promising Potential - Apr 24th, 2026 4:38 am
European Equities Traded in US as ADRs Ease in Thursday Trading - Apr 23rd, 2026 9:04 am
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading - Apr 21st, 2026 9:14 am
A Look At argenx (ENXTBR:ARGX) Valuation After New VYVGART Data At The 2026 AAN Meeting - Apr 20th, 2026 1:06 pm
The Bull Case For argenx (ENXTBR:ARGX) Could Change Following New VYVGART Ocular MG Efficacy Data - Apr 20th, 2026 12:05 pm
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP - Apr 17th, 2026 11:00 pm
European Equities Traded in the US as American Depositary Receipts Declining in Thursday Trading - Apr 16th, 2026 9:05 am
European Equities Traded in the US as American Depositary Receipts Trending Lower in Wednesday Trading - Apr 15th, 2026 9:12 am
European Equities Traded in the US as American Depositary Receipts Track Lower in Tuesday Trading - Apr 7th, 2026 9:11 am
Exploring 3 Leading High Growth Tech Stocks In Europe - Mar 25th, 2026 11:38 pm
CSLLY or ARGX: Which Is the Better Value Stock Right Now? - Mar 24th, 2026 9:40 am
CSLLY vs. ARGX: Which Stock Is the Better Value Option? - Mar 23rd, 2026 9:40 am
argenx announces Annual General Meeting of Shareholders on May 6, 2026 - Mar 20th, 2026 2:01 pm
Argenx Data At AAN Puts VYVGART Neuromuscular Upside In Focus - Mar 18th, 2026 6:17 pm
Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference - Mar 17th, 2026 11:06 pm
Analysts Highlight Vyvgart Expansion as Major Growth Driver for Argenx (ARGX) - Mar 17th, 2026 6:07 am
Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics - Mar 16th, 2026 5:00 am
Deutsche Bank lifts Argenx to Buy as valuation ’no longer demanding’ - Mar 11th, 2026 6:36 am
Assessing Argenx (ENXTBR:ARGX) Valuation After First-Year Profitability And Positive VYVGART Phase 3 Results - Mar 9th, 2026 11:10 pm
Argenx (ARGX) 2025 Net Product Sales Rise 90% to $4.2B as First Annual Profit Reached - Mar 9th, 2026 6:14 pm